These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12722735)

  • 41. Functional profile of almotriptan in animal models predictive of antimigraine activity.
    Gras J; Bou J; Llenas J; Fernández AG; Palacios JM
    Eur J Pharmacol; 2000 Dec; 410(1):43-51. PubMed ID: 11134655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan.
    den Boer MO; Villalón CM; Heiligers JP; Humphrey PP; Saxena PR
    Br J Pharmacol; 1991 Feb; 102(2):323-30. PubMed ID: 1849764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of subcutaneous sumatriptan on plasma growth hormone concentrations in migraine patients.
    Pinessi L; Rainero I; Savi L; Valfrè W; Limone P; Calvelli P; Del Rizzo P; Gianotti L; Taliano M; Ghigo E; Arvat E
    Cephalalgia; 2000 May; 20(4):223-7. PubMed ID: 10999671
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT1D receptor agonist PNU-142633.
    McCall RB; Huff R; Chio CL; TenBrink R; Bergh CL; Ennis MD; Ghazal NB; Hoffman RL; Meisheri K; Higdon NR; Hall E
    Cephalalgia; 2002 Dec; 22(10):799-806. PubMed ID: 12485205
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. A comment.
    Maggioni F; Pini LA; Zanchin G
    Cephalalgia; 2011 Jul; 31(9):1061. PubMed ID: 21511951
    [No Abstract]   [Full Text] [Related]  

  • 46. 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks.
    Olesen J
    Cephalalgia; 2010 Oct; 30(10):1157-8. PubMed ID: 20855360
    [No Abstract]   [Full Text] [Related]  

  • 47. Operational characteristics of the 5-HT1-like receptors mediating external carotid vasoconstriction in vagosympathectomized dogs. Close resemblance to the 5-HT1D receptor subtype.
    Villalón CM; Sánchez-López A; Centurión D
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Nov; 354(5):550-6. PubMed ID: 8938651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of sumatriptan on cerebral blood flow during migraine headache: measurement by sequential SPECT used 99mTc-ECD background subtraction method].
    Ueda T; Torihara Y; Tsuneyoshi N; Ikeda Y
    No To Shinkei; 2001 Jul; 53(7):625-30. PubMed ID: 11517486
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacology of antimigraine drugs.
    Saxena PR; Den Boer MO
    J Neurol; 1991; 238 Suppl 1():S28-35. PubMed ID: 1646288
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
    Villalón CM; VanDenBrink AM
    Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks].
    Stepień A
    Pol Merkur Lekarski; 1999 Jun; 6(36):341-3. PubMed ID: 10481551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis.
    Sakai Y; Dobson C; Diksic M; Aubé M; Hamel E
    Neurology; 2008 Feb; 70(6):431-9. PubMed ID: 18250288
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetized dogs are not of the 5-HT1A or 5-HT1D subtype.
    Perren MJ; Feniuk W; Humphrey PP
    Br J Pharmacol; 1991 Jan; 102(1):191-7. PubMed ID: 1675143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
    Kayser V; Aubel B; Hamon M; Bourgoin S
    Br J Pharmacol; 2002 Dec; 137(8):1287-97. PubMed ID: 12466238
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine.
    Gras J; Cardelús I; Llenas J; Palacios JM
    Eur J Pharmacol; 2000 Dec; 410(1):53-9. PubMed ID: 11134656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sumatriptan-nonresponders: a survey in 366 migraine patients.
    Visser WH; de Vriend RH; Jaspers NH; Ferrari MD
    Headache; 1996 Sep; 36(8):471-5. PubMed ID: 8824001
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic advances in migraine.
    Solomon GD
    J Clin Pharmacol; 1993 Mar; 33(3):200-9. PubMed ID: 8385160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of sumatriptan on visual aura symptoms in migraine.
    Schoenen J
    Headache; 1993 Mar; 33(3):164. PubMed ID: 8387475
    [No Abstract]   [Full Text] [Related]  

  • 59. Migraine revolution and sumatriptan.
    Palmer JB; Salonen R
    Lancet; 2000 Jun; 355(9222):2250-1. PubMed ID: 10881915
    [No Abstract]   [Full Text] [Related]  

  • 60. Almotriptan: a review of its use in migraine.
    Keam SJ; Goa KL; Figgitt DP
    Drugs; 2002; 62(2):387-414. PubMed ID: 11817980
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.